%PDF-1.4
%
56 0 obj
<>
endobj
53 0 obj
<>
endobj
108 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-24T13:37:36Z
2024-03-28T08:28:21-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T08:28:21-07:00
application/pdf
Heather
201101.omeract
uuid:4b24a2c4-1dd2-11b2-0a00-5909275dc400
uuid:4b24a2c6-1dd2-11b2-0a00-810000000000
endstream
endobj
40 0 obj
<>
endobj
42 0 obj
<>
endobj
41 0 obj
<>
endobj
43 0 obj
<>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
31 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
114 0 obj
[118 0 R]
endobj
115 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5295 Tm
(rheumatoid arthritis. Br J Rheumatol 1988;27:375-80.)Tj
-2.175 -1.25 Td
[(60.)-875 (Bellamy N, )54.9 (Anastassiades )17.8 (TP)110.8 (, Buchanan )17.8 (WW)91.8 (, et al. Rheumatoid)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(arthritis antirheumatic drug trials. I. Ef)17.7 (fects of standardization)]TJ
0 Tc 0 -1.25 TD
(procedures on observer dependent outcome measures. J Rheumatol)Tj
0 Tw T*
(1991;18:1893-900.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(61.)-875.1 (Pincus )17.7 (T)73.9 (, Summey J, Soraci S, )17.7 (W)79.7 (allston K, Hummon N.)]TJ
0 Tc 2.175 -1.25 Td
(Assessment of patient satisfaction in activities of daily living using)Tj
-0.00011 Tc T*
[(a modified Stanford Health )54.8 (Assessment Questionnaire. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1983;26:1346-53.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(62.)-875.1 (Ekdahl C, Eberhardt K, )54.8 (Andersson SI, Svensson B. )54.8 (Assessing)]TJ
0 Tc 2.175 -1.25 Td
(disability in patients with rheumatoid arthritis. Use of a Swedish)Tj
-0.00011 Tc T*
[(version of the Stanford Health )54.8 (Assessment Questionnaire. Scand J)]TJ
0 Tc T*
(Rheumatol 1988;17:263-71.)Tj
-2.175 -1.25 Td
[(63.)-875 (van der Heijde D, van Riel PL, van de Putte LB. Sensitivity of a)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Dutch Health )54.8 (Assessment Questionnaire in a trial comparing)]TJ
0 Tc T*
(hydroxychloroquine vs sulphasalazine. Scand J Rheumatol)Tj
0 Tw T*
(1990;19:407-12.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(64.)-875.1 (Ferraz MB, Oliveira LM, )54.8 (Araujo PM, )54.8 (Atra E, )17.7 (T)34.8 (ugwell P)110.7 (.)]TJ
0 Tc 2.175 -1.25 Td
(Crosscultural reliability of the physical ability dimension of the)Tj
T*
[(Health )54.9 (Assessment Questionnaire. J Rheumatol 1990;17:813-7.)]TJ
-2.175 -1.25 Td
[(65.)-875 (Guillemin F)79.8 (,)0.1 ( Briancon S, Pourel J. )17.7 (V)111.1 (alidity and discriminant ability)]TJ
2.175 -1.25 Td
(of the HAQ Functional Index in early rheumatoid arthritis. Disabil)Tj
T*
(Rehabil 1992;14:71-7.)Tj
-2.175 -1.25 Td
[(66.)-875 (Ranza R, Marchesoni )54.9 (A, Calori G, et al. )17.8 (The Italian version of the)]TJ
2.175 -1.25 Td
[(Functional Disability Index of the Health )54.9 (Assessment)]TJ
T*
[(Questionnaire. )54.9 (A)-219.8 (reliable instrument for multicenter studies on)]TJ
T*
[(rheumatoid arthritis. Clin Exp Rheumatol 1993;1)36.9 (1:123-8.)]TJ
-2.175 -1.25 Td
[(67.)-875 (Cardiel MH, )54.8 (Abello Banfi M, Ruiz Mercado R, )54.8 (Alarcon Segovia D.)]TJ
2.175 -1.25 Td
(How to measure health status in rheumatoid arthritis in non-English)Tj
T*
(speaking patients: validation of a Spanish version of the Health)Tj
-0.00011 Tc T*
(Assessment Questionnaire Disability Index \(Spanish HAQ-DI\).)Tj
0 Tc T*
[(Clin Exp Rheumatol 1993;1)36.9 (1:1)36.9 (17-21.)]TJ
-2.175 -1.25 Td
[(68.)-875 (Estevevives J, Batllegualda E, Reig )54.9 (A, et al. Spanish version of the)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Health )54.8 (Assessment Questionnaire: reliability)64.8 (, validity and)]TJ
0 Tc T*
[(transcultural equivalency)64.9 (. J Rheumatol 1993;20:21)36.9 (16-22.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(69.)-875.1 (Ferraz MB, Quaresma MR, )54.8 (Aquino LRI, )54.8 (Atra E, )17.7 (T)34.8 (ugwell P)110.7 (,)]TJ
0 Tc 2.175 -1.25 Td
(Goldsmith CH. Reliability of pain scales in the assessment of)Tj
T*
(literate and illiterate patients with rheumatoid arthritis. J Rheumatol)Tj
0 Tw T*
(1990;17:1022-4.)Tj
0.0249 Tw -2.175 -1.25 Td
[(70.)-875 (Pincus )17.7 (T)74 (, )17.7 (W)79.8 (olfe F)79.8 (, Callahan LF)79.8 (. Introduction: updating a)]TJ
2.175 -1.25 Td
(reassessment of traditional paradigms concerning rheumatoid)Tj
T*
[(arthritis. In: )17.7 (W)79.8 (olfe F)79.8 (,)0.1 ( Pincus )17.7 (T)74 (, editors. Rheumatoid arthritis:)]TJ
T*
[(pathogenesis, assessment, outcome and treatment. New )36.9 (Y)100.1 (ork:)]TJ
-0.00011 Tc T*
(Marcel Dekker; 1994:1-74.)Tj
-2.175 -1.25 Td
[(71.)-875.1 (Dawes PT)73.9 (, Fowler PD, Clarke S, Fisher J, Lawton )54.8 (A, Shadworth)]TJ
0 Tc 2.175 -1.25 Td
[(MF)79.8 (. Rheumatoid arthritis: treatment which controls the C-reactive)]TJ
T*
(protein and erythrocyte sedimentation rate reduces radiological)Tj
T*
(progression. Br J Rheumatol 1982;25:44-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(72.)-875.1 (Pullar )17.7 (T)73.9 (, Hunter JCHA. Does second line therapy af)17.7 (fect the)]TJ
0 Tc 2.175 -1.25 Td
[(radiological progression of rheumatoid arthritis? )54.8 (Ann Rheumatic)]TJ
T*
(Dis 1984;43:18-23.)Tj
30.825 62.5 Td
[(73.)-875 (Scott D, Coulton B, Bacon P)110.8 (,)0.1 ( Popert )54.8 (A. Methods of x-ray)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(assessment in rheumatoid arthritis. )54.8 (A)-219.9 (re-evaluation. Br J Rheumatol)]TJ
0 Tc 0 Tw T*
(1985;24:31-9.)Tj
0.0249 Tw -2.175 -1.25 Td
[(74.)-875 (Sharp JT)74 (, Bluhm GB, Brook )54.8 (A, et al. Reproducibility of multiple-)]TJ
2.175 -1.25 Td
(observer scoring of radiologic abnormalities in the hands and wrists)Tj
T*
[(of patients with rheumatoid arthritis. )54.9 (Arthritis Rheum 1985;)]TJ
0 Tw T*
(28:16-24.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(75.)-875.1 (Fries JF)79.7 (, Bloch DA, Sharp JT)73.9 (, et al. )54.8 (Assessment of radiologic)]TJ
2.175 -1.25 Td
[(progression in rheumatoid arthritis. )54.8 (A)-219.9 (randomized, controlled trial.)]TJ
0 Tc T*
(Arthritis Rheum 1986;29:1-9.)Tj
-2.175 -1.25 Td
[(76.)-875 (Nance E, Kaye J, Callahan L, et al. Observer variation in)]TJ
-0.00011 Tc 2.175 -1.25 Td
(quantitative assessment of rheumatoid arthritis: Part I. Scoring)Tj
0 Tc T*
(erosions and joint space narrowing. Invest Radiol 1986;21:922-7.)Tj
-2.175 -1.25 Td
[(77.)-875 (Kaye J, Nance E, Callahan L, et al. Observer variation in)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(quantitative assessment of rheumatoid arthritis. II. )54.8 (A)-219.9 (simplified)]TJ
0 Tc T*
(scoring system. Invest Radiol 1987;22:41-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(78.)-875.1 (van der Heijde D, van Riel PL, Nuver Zwart IH, Gribnau FW)91.7 (, van)]TJ
0 Tc 2.175 -1.25 Td
[(de Putte L. Ef)17.8 (fects of hydroxychloroquine and sulphasalazine on)]TJ
T*
(progression of joint damage in rheumatoid arthritis. Lancet)Tj
0 Tw T*
(1989;1:1036-8.)Tj
0.0249 Tw -2.175 -1.25 Td
[(79.)-875 (Cuchacovich M, Couret M, Peray P)110.8 (,)0.1 ( Gatica H, Sany J. Precision of)]TJ
2.175 -1.25 Td
(the Larsen and the Sharp methods of assessing radiologic change in)Tj
T*
[(patients with rheumatoid arthritis. )54.9 (Arthritis Rheum 1992;35:736-9.)]TJ
-2.175 -1.25 Td
[(80.)-875 (Salaf)17.8 (fi F)79.8 (, Ferraccioli G, Peroni M, Carotti M, Bartoli E, Cervini C.)]TJ
-0.00011 Tc 2.175 -1.25 Td
(Progression of erosion and joint space narrowing scores in)Tj
0 Tc T*
(rheumatoid arthritis assessed by nonlinear models. J Rheumatol)Tj
0 Tw T*
(1994;21:1626-30.)Tj
0.0249 Tw -2.175 -1.25 Td
[(81.)-875 (Scott DL, Houssien DA, Laasonen L. Proposed modification to)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Larsen\222)54.8 (s scoring methods for hand and wrist radiographs. Br J)]TJ
0 Tc T*
(Rheumatol 1995;34:56.)Tj
-2.175 -1.25 Td
[(82.)-875 (V)111.1 (an der Heijde D, van Leeuwen M, van Riel P)110.8 (, van de Putte L.)]TJ
2.175 -1.25 Td
(Radiographic progression on radiographs of hands and feet during)Tj
T*
(the first 3 years of rheumatoid arthritis measured according to)Tj
T*
[(Sharp\222)54.9 (s method \(van der Heijde modification\). J Rheumatol)]TJ
0 Tw T*
(1995;22:1792-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(83.)-875.1 (Fex E, Johnson U, Johnson K, Eberhardt K. Development of)]TJ
0 Tc 2.175 -1.25 Td
(radiographic damage during the first 5-6 years of rheumatoid)Tj
-0.00011 Tc T*
[(arthritis. )54.8 (A)-219.9 (prospective follow up study of a Swedish cohort. Br J)]TJ
0 Tc T*
[(Rheumatol 1996;35:1)36.9 (106-15.)]TJ
-2.175 -1.25 Td
[(84.)-875 (Bolten )17.8 (W)91.8 (, Brocal D, Sangha O, Kaser R. Reduced radiographic)]TJ
2.175 -1.25 Td
[(joint counts in rheumatoid arthritis [abstract]. )54.8 (Arthritis Rheum)]TJ
T*
(1997;40 Suppl 9:S289.)Tj
ET
0 0 0 0 scn
465 777 92 -27 re
f*
468 770 90 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Lasser)36.9 (e, et al: Reliability of measur)36.9 (es of RA)]TJ
0 Tw 61.4375 -0.0313 Td
(903)Tj
ET
0 0 0 0 scn
/GS0 gs
102.06 59.08 407.5 -10.83 re
f*
0.5 w
102.06 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
83 0 obj
<>
endobj
113 0 obj
<>
endobj
66 0 obj
<>
endobj
59 0 obj
<>
endobj
61 0 obj
<>
endobj
78 0 obj
<>stream
HV PTW=A1*B}״ҭfЈqE\PZThJь&F)'A_I,ƨq+e%q,$Zes~[R558ww߹~ * gkY]Ɵf-vdAi,7k-`f@*(ڱ0 Oqٴ.0#PioY 6
_o`ӣZ5%K@F̚]{-ZK94,+BoJ6o=03|z͞7ߺMfFEeodB:'hɲ\VJXg+u;Tm}$s&4~\Z,mԢ#1U#N؈LqglG />G(4do\O8ؙ\5It8.Pk
#(RTY;FF;L(%w'N2/'9hKDv#hĐO'qܱGD!\jn` "+
ΊrRcy7v?,zs':dD_
)h=1q'aqEDb8%}[YVc=$2/2t=SɫgԐ5 &bL/b9[?Rl]3섓N0#u{A2Z?wQvp&"BtY*}+h'
9H^P2lzYB<+ߚc},;sNc22rv{1{g%+1Sް;OgIqp"JpĊdTf9b(EX"*rH_#''ErJw!*JbC -ZUhNGGC=CCCziE[Vdղ?+d1#7m Ř,`5׳>}tٝ`
3xPYDtх
aFcEd1E1G%*J*."v]‸&n;l&d+Lvf
\'ߗr4yQJ)ÕJ@T)[mvqAy3mJ/Phyۺ\LSdSM̖MÑMgfh} V2W`?#(L3@}D3o]Nx*>^V5єE,ʡߖ(
{MgL,?X(2|?C7#AFIp5O
е;)SgO3\+m7yW,kGO|άKXŒչs_WK'5yؘ'U6Ufa: LO``LZjh4x^h8Rc~xmfd9S6ڀ;lkf[
9c Or-[YT
fFYԶ7߶{l͵--O
=5#Ҟk+ca.
m!D 5#""O!K{`?MF2QQ&